Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Sagimet Biosciences Inc. Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 October 29, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024 October 16, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology October 11, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH October 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit September 12, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences to Participate in Two Upcoming Investor Conferences September 04, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates August 14, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors August 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers BRNS RCUS SGMT SNDX Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat June 10, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 June 06, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 May 16, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates May 15, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 May 07, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer May 06, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 April 22, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat March 27, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors March 25, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers IPSC MIRM RPHM SGMT Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates March 25, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences to Participate in Two Upcoming Investor Conferences February 29, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock January 25, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock January 23, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH January 22, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic December 04, 2023 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit November 28, 2023 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference November 22, 2023 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates November 13, 2023 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023 October 24, 2023 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference October 18, 2023 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma September 27, 2023 From Sagimet Biosciences Inc. Via GlobeNewswire Tickers SGMT Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
